Technology & innovation

This archive covers technology and innovation breakthroughs that improve lives, protect the environment, and expand human possibility. From medical devices to clean energy tools, the stories here focus on what’s working and who’s making it happen.

Insulin pens, for article on duodenal mucosal resurfacing

New treatment eliminates insulin for 86% of patients in early trials

By / / Good News For Humankind

A one-hour outpatient procedure helped 12 of 14 Type 2 diabetes patients stop using insulin entirely and stay off it for a full year. Researchers at Amsterdam University Medical Center used a catheter to deliver gentle electrical pulses to the lining of the small intestine, prompting the tissue to regenerate and apparently restoring the body’s natural insulin response. By comparison, the widely used medication semaglutide alone helps only about one in five patients discontinue insulin. The team calls the approach “disease-modifying” because it targets the root cause rather than the symptoms, and a larger randomized trial is now in the works. If the results hold, it could reshape how a condition affecting hundreds of millions worldwide is treated.

Ovarian and Cervical Cancer Awareness. a Teal Ribbon, for article on cervical cancer treatment

New cervical cancer treatment regime ‘cuts risk of dying from disease by 40%’

By / / Good News For Humankind

Cervical cancer treatment just took its biggest leap in 25 years, and the breakthrough comes from a surprisingly simple idea: changing the timing. In a trial spanning the U.K., Mexico, India, Italy, and Brazil, women who received a short course of chemotherapy before standard chemoradiation were 40% less likely to die from the disease. Even better, the drugs involved are already approved, affordable, and widely available — meaning hospitals could adopt this approach without waiting on a new wonder drug. For the hundreds of thousands of women diagnosed each year, especially in lower-income countries where cervical cancer hits hardest, it’s a rare kind of medical good news: a major gain that’s actually within reach.

Virus up close, for article on lenacapavir HIV prevention

‘Gamechanger’ HIV prevention drug to be made available cheaply in 120 countries

By / / Good News For Humankind

Lenacapavir, a twice-yearly HIV prevention shot with near-perfect results in clinical trials, is about to become far more affordable for millions of people. Gilead Sciences has licensed six generic manufacturers across India, Egypt, Pakistan, and the U.S. to produce the drug for 120 lower-income countries, where researchers estimate it could eventually be made for as little as $40 per patient per year. In trials among cisgender women in South Africa and Uganda, not a single participant who received the injection contracted HIV. Advocates are urging wider access, since much of Latin America was left out of the deal. Still, it’s a hopeful signal that breakthrough prevention tools can reach the people who need them most — fast.

image for article on mpox diagnostic test

World Health Organization approves first mpox diagnostic test for emergency use

By / / Good News For Humankind

The first mpox diagnostic test has been cleared through the World Health Organization’s Emergency Use Listing, opening a faster procurement route for the countries hit hardest by the outbreak. Abbott’s Alinity m MPXV assay detects both clades of the virus from rash samples, and UN agencies can now order it directly for places where national approval pathways would otherwise take months. That speed matters: in 2024, only 37% of suspected mpox cases in the Democratic Republic of the Congo were confirmed by testing, leaving outbreaks harder to trace. Three more tests are already under WHO review, with more manufacturers in talks. It’s a hopeful signal that the world is learning from past pandemics — building diverse, quality-assured tools before bottlenecks become catastrophes.

image for article on ovarian cancer prevention vaccine

Scientists in the U.K. developing world’s first vaccine to prevent ovarian cancer

By / / Good News For Humankind

OvarianVax, in development at the University of Oxford, has just received up to £600,000 from Cancer Research U.K. to pursue the world’s first vaccine designed to prevent ovarian cancer before it begins. The idea is to train the immune system to recognize over 100 proteins found on early-stage ovarian cancer cells, then destroy those cells before they can spread. For women carrying BRCA gene mutations, who currently face the wrenching choice of preventive surgery that ends fertility and triggers early menopause, a vaccine could transform what’s possible. It’s still early days, with lab work and clinical trials ahead, but the project signals a real shift in cancer research: moving from treatment toward prevention, and giving high-risk women better options worldwide.

A close-up of a medical syringe and insulin vial for an article about stem cell therapy for type 1 diabetes, for article on stem cell therapy type 1 diabetes

Chinese researchers reverse type 1 diabetes using a patient’s own stem cells

By / / Good News For Humankind

Type 1 diabetes reversal using a patient’s own stem cells marks a historic milestone in medicine. A 25-year-old woman in China received a transplant of insulin-producing cells reprogrammed from her own body, and within three months was generating insulin naturally — eventually eliminating her need for external injections entirely. Published in Cell in 2024, the research is significant because it bypasses donor tissue and immunosuppressant drugs entirely, dramatically reducing rejection risk. For the roughly 8.4 million people worldwide living with type 1 diabetes, this proof of concept offers a genuinely new direction for treatment.

Medical researcher in a lab examining vials related to asthma and COPD treatment and mRNA vaccine development, for article on benralizumab injection, for article on mRNA lung cancer vaccine

World’s first mRNA lung cancer vaccine enters human trials in seven countries

By / / Good News For Humankind

A landmark mRNA lung cancer vaccine is now being tested in human patients for the first time, marking a historic milestone in cancer treatment. BNT116, developed by BioNTech, uses the same messenger RNA technology behind COVID-19 vaccines to train the immune system to recognize and destroy non-small cell lung cancer cells. The phase 1 trial spans 34 sites across seven countries, with roughly 130 patients enrolled. Unlike chemotherapy, this approach targets only tumor cells, potentially offering a more precise and lasting defense against the world’s deadliest cancer, which kills 1.8 million people annually.

Fervo Energy geothermal plant, for article on enhanced geothermal power purchase agreement

World’s biggest geothermal power purchase agreement completed in western U.S.

By / / Good News For Humankind

A Utah geothermal project just secured what developers are calling the world’s largest geothermal power purchase agreement — a 15-year deal to deliver 320 megawatts of always-on clean electricity to Southern California Edison, enough to power roughly 350,000 homes. Fervo Energy’s Cape Station plant uses horizontal drilling borrowed from the oil and gas industry to circulate water through deep hot rock, unlocking geothermal power in places where it was never viable before. First electrons are expected to flow in 2026, with the rest coming online by 2028. For a clean grid that needs to run when the sun sets and the wind stops, this kind of steady, weather-proof power may be the missing piece — and a signal that geothermal is ready for prime time.

Good news for public health, for article on CAB-LA HIV prevention, for article on lenacapavir HIV prevention, for article on HIV infections in young men

New twice-yearly shot to prevent HIV achieves 100% success rate in late-stage trial

By / / Good News For Humankind

Lenacapavir, a twice-yearly HIV prevention shot, protected every single one of 2,134 women who received it in a late-stage trial across South Africa and Uganda — a 100% efficacy result so striking that monitors ended the blinded phase early. The breakthrough matters because daily prevention pills, while powerful in theory, often falter in real life: stigma, forgotten doses, and disrupted routines all chip away at protection. Two clinic visits a year, by contrast, means a full year of coverage. The remaining hurdle is access, with advocates pressing manufacturer Gilead to license generic versions for the regions hardest hit. If that happens, a tool this effective could reshape the global push to end the HIV epidemic by 2030.

X-ray image of the intestine, for article on dostarlimab bowel cancer trial

New bowel cancer drug is found to be 100% effective

By / / Good News For Humankind

Immunotherapy just delivered something almost unheard of in cancer research: every single one of 42 patients in a rectal cancer trial showed no detectable tumour after treatment with the drug dostarlimab. Even more encouraging, the first 24 patients have now been tracked for an average of 26 months, and their cancers haven’t come back. For people with this specific subtype, it could mean skipping the chemotherapy, radiation, and surgery that often leave lasting damage. Larger studies are now underway to confirm the findings, but the signal is remarkable. It’s a glimpse of where cancer care may be heading worldwide — treatments that work with the body’s own immune system, and let patients keep their lives intact.